Four-year data from a phase 3 study examined the durability of glycemic response with dapagliflozin as add-on therapy to metformin vs. glipizide in patients with type 2 diabetes inadequately controlled with metformin alone. The data was presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
Insulin degludec/insulin aspart (Ryzodeg, Novo Nordisk) administered twice daily, provides successful glycemic control with fewer injections than a basal-bolus regimen, according to data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria.
As many as 11.4 million antibiotic prescriptions written each year for children and teens may be unnecessary, according to a study in the October 2014 issue of Pediatrics, published online Sept. 15.
Liraglutide 3 mg (Saxenda, Novo Nordisk) has been recommended by an FDA Advisory Committee to be approved for use in the treatment of obesity
FDA has approved a new treatment option for opioid-induced constipation in adult patients with chronic noncancer pain. Naloxegol (Movantik, AstraZeneca) tablets C-II is the first once-daily, oral, peripherally acting µ-opioid receptor antagonist (PAMORA) to be approved for this condition.
About 1,000 cases of the respiratory illness caused by Enterovirus D68 have been confirmed in 10 states in the United States so far. Many of these children are being hospitalized for it.
FDA has approved a combination of the generic drugs naltrexone and bupropion (Contrave) for chronic weight management in obese adults (body mass index [BMI] >30 kg/m2). This combination agent has also been approved for use in those patients who are overweight (BMI >27 kg/m2) and have at least one weight-related comorbid condition such as diabetes, hypertension, or dyslipidemia.
Medication-related problems (MRPs) can be a significant patient safety risk, particularly in hospitalized patients. One method used to minimize this safety concern is through medication reconciliation, or the process of documentation of a patient’s outpatient medication list at the time of hospital admission. Medication reconciliation can be performed by any trained health care professional (i.e. nurses, pharmacy technicians, physicians, etc.), however improved patient safety outcomes have been demonstrated when pharmacists perform this process.
In 1983, the United States enacted the Orphan Drug Act (ODA). An analogous law was passed in Europe in 2000. Both pieces of legislation are considered major successes in terms of spurring the development of orphan drugs. To illustrate, in the decade prior to 1983 only 34 orphan products were marketed, whereas in the past year alone 9 orphan drugs were launched. In the past 5 years, 39 orphan drugs were launched in the US across numerous therapeutic categories, including multiple myeloma, chronic myeloid leukemia, metastatic non-small cell lung cancer, hemophilia, tuberculosis, homozygous familial hypercholesterolemia, and cystic fibrosis.1
Industry updates in business and health management
Nursing home residents with advanced dementia often receive medications of questionable benefit with costly consequences, according to a study published online September 8 in the Journal of the American Medical Association Internal Medicine.
Looming rate cuts and policy changes fuel grassroots effort
Conflicting appellate decisions cause confusion for federal exchange beneficiaries
Payers and providers can stop hemorrhaging administrative costs by investing in technology
FDA has approved Ferric Citrate (Keryx), an oral, iron-based therapy for the control of serum phosphorus levels in chronic kidney disease (CKD) patients on dialysis.
An investigational extended-release oral formulation of hydrocodone and acetaminophen the treatment of moderate to moderately severe acute pain was more effective than placebo at providing rapid and consistent pain relief in patients 48-hours post-surgery, according to a recent data presented at PAINWeek 2014 in Las Vegas.
Nationwide Children’s Hospital is one of 13 medical centers nationwide participating in the Pediatric Regional Anesthesia Network, a collaboration designed to support the collection of highly audited data on practice patterns and complications and to facilitate collaborative research in regional anesthetic techniques in infants and children. Participating institutions report the number of regional anesthesia procedures they do each month. Researchers conducted this study at Nationwide Children’s Hospital in Columbus, Ohio, publishing its results in the Journal of Pediatric Orthopaedics in June.
The US Preventive Services Task Force (USPSTF) published a final recommendation statement recommending that women at high risk for preeclampsia use low-dose aspirin (81 mg/day) after 12 weeks of pregnancy to prevent the condition and its related health problems.
Market readies for explosion of new technology, drugs
ACA base standard "relatively tight"
Patient care as well as the financial health of oncologists should be strengthened
WellPoint opted to change its corporate name to Anthem, Inc. in mid-August. Here’s why.
Experts anticipate plans with up to seven levels
FDA actions in brief, fast-track designations, priority review, orphan drug designations
Plans tackle cancer treatment
Transform care through innovative payment strategies
Dalvance (dalbavancin) is the first and only intravenous antibiotic was approved on May 2014 to treat ABSSSIs with a 2-dose regimen of 1,000 mg once week and later on a 500 mg that is given over a 30-minute time span
Patients with heart failure and reduced ejection fraction (HF-REF) treated with an investigational angiotensin receptor neprilysin Inhibitor (ARNI) are more likely to reduce cardiovascular death and heart failure hospitalization than those given ACE inhibitors or ARBs as first-line therapy in heart failure, according to data presented at the European Society of Cardiology congress in Barcelona, Spain, and published simultaneously in the New England Journal of Medicine.
FDA has approved pembrolizumab (Keytruda, Merck) for treatment of patients with advanced or unresetable melanoma who are no longer responding to other drugs.
